Author’s response to reviews

Title: Comparative study of sickle cell anemia and hemoglobin SC disease: clinical characterization, laboratory biomarkers and genetic profiles

Authors:

Milena Aleluia (milena.aleluia@gmail.com)
Teresa Fonseca (ruiteresafonseca@uol.com.br)
Regiana Souza (regianaquinto@hotmail.com)
Fábia Neves (fabia_neves83@yahoo.com.br)
Caroline Guarda (cguarda4@hotmail.com)
Rayra Santiago (rayrasantiago@hotmail.com)
Bruna Cunha (brunal.a.cunha@gmail.com)
Camylla Figueiredo (myllavilas@hotmail.com)
Sânzio Santana (sanziobiomedico@hotmail.com)
Silvana Paz (spaz@bahia.fiocruz.br)
Júnia Ferreira (juniadutra@gmail.com)
Bruno Cerqueira (brunoveloso2@hotmail.com)
Marilda Gonçalves (mari@bahia.fiocruz.br)

Version: 3 Date: 25 Jul 2017

Author’s response to reviews:

July, 25th, 2017

To: Afsaneh Khetrapal, MD

BMC Hematology Editorial Office

bmchematol@biomedcentral.com
From: Authorship of the manuscript entitled “Comparative study of sickle cell anemia and hemoglobin SC disease: clinical characterization, laboratory biomarkers and genetic profiles” (BMC Hematology - BHEM-D-16-00045R2).

Subject: Rebuttal letter

Dear Dr. Khetrapal,

Thank you for allowing us to revise our manuscript entitled “Comparative study of sickle cell anemia and hemoglobin SC disease: clinical characterization, laboratory biomarkers and genetic profiles” (BMC Hematology - BHEM-D-16-00045R2). We thank the reviewer for the careful perusal of our manuscript and thoughtful comments, which certainly have improved it. We would like to say that we accepted all comments raised by the review. We have addressed each reviewer comments, as described below. We would like to thank you for your kindly to let us revised our previous version. We remain available for further clarifications and adjustments that are necessary and we hope that the manuscript is now suitable for publication.

Sincerely,

Marilda de Souza Goncalves, Ph.D.
1. Data access

Please detail how you received permission to access the clinical data you used from the patient medical records, as mentioned in your Methods section.

Answer: The study was approved by the Ethics Research Board of Gonçalo Moniz Institute/Oswaldo Cruz Foundation (IGM-FIOCRUZ-BA) allowing the permission to access the clinical data from the patient medical records. The study was approved under 08452913.9.0000.0040 protocol number.

2. Availability of data and material

Thank you for providing us with this statement as part of your declarations, however, the statement "The dataset supporting the conclusions of this article is included within the article" is invalid. This is because Availability of Data and Materials refers to the raw data-set upon which the summary statistics in the manuscript are based.

Please detail where the data supporting your findings can be found - including information in any supplementary files. If you do not wish to share your data or unable to do so, please state that data will not be shared, together with a valid reason.

If the raw data is the patient dataset, which contains patient identifying information, then this cannot be provided. Instead, please use one of the following and adapt as appropriate:

- The datasets generated during and/or analysed during the current study are available in the [NAME] repository, [PERSISTENT WEB LINK TO DATASETS]

- The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.
• The datasets generated during and/or analysed during the current study are not publicly available due [REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.

• The datasets generated during the current study are not publicly available due [REASON WHY DATA ARE NOT PUBLIC].

Answer: The datasets generated during and/or analyzed during the current study are not available to be published because the data are related with the medical records of the patients followed in the CERDOFI however; the data are available from the corresponding author on reasonable request.

3. Image attribution

Please state in the cover letter whether the map depicted in the figure 1 is your own or obtained from another source. If from another source, then please acknowledge the source in the figure legend, and if it is under copyright also state the written permission given to use and adapt it for publication purposes.

If the above conditions are not met the image needs to be removed. Please note the editors may request proof of permission at any time.

Answer: The authors designed the figure 1.